ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Pediatric Recurrent Respiratory Papillomatosis: Fighting the Battle of a Rare But Serious Disease

by Rabiya S. Tuma, PhD • October 1, 2006

  • Tweet
  • Email
Print-Friendly Version

Andrew F. Inglis Jr., MD, Associate Professor in the Division of Pediatric Otolaryngology at Children’s Hospital & Medical Center at the University of Washington in Seattle, is an outspoken critic of the use of cidofovir in RRP. In an editorial he wrote for The Annals of Otology, Rhinology, and Laryngology last year, Dr. Inglis pointed out that the doses used in RRP treatment lead to systemic drug levels that induced tumors and kidney toxicity in rats during short-term toxicity testing. Twenty percent of the rats in the study developed cancers, despite the fact that the toxicity tests were not the long-term studies typically used to look for cancer formation in animal models. The impact of RRP on some patients is so truly devastating that they would gladly assume the still-theoretical risk of cidofovir-induced human malignancy. On the other hand, the physician should be aware of the results of the animal studies with this drug, and put them in the proper perspective for the patient, he concluded.

You Might Also Like

No related posts.

Explore This Issue
October 2006

In the absence of a randomized controlled trial, several groups are trying to follow patients treated with cidofovir to determine whether benign warts are converting to precancerous or cancerous lesions at a higher-than-expected rate. For example, Richard J. Smith, MD, Professor and Vice Head of the Department of Otolaryngology at the University of Iowa, and colleagues are collecting pathology samples, treatment data, and HPV type on RRP patients treated in the university health care system. No data are yet available however.

Novel Adjuvant Agents

Farrel J. Buchinsky, MD, PhD

Farrel J. Buchinsky, MD, PhD

In addition to cidofovir and interferon, two other agents look promising in the treatment of RRP: celecoxib, which is a cyclooxygenase (COX)-2 inhibitor, and a novel immune modulatory agent called HspE7. Preliminary data suggest that both agents reduce the severity of disease. Unfortunately, pivotal studies for each drug have been delayed because of a lack of funding.

Researchers at Long Island Jewish Medical Center in New Hyde Park, N.Y., have designed a multicenter randomized placebo-controlled trial to determine whether the use of celecoxib can reduce the frequency of surgery in adult RRP patients. While awaiting NIH funding for the multicenter study, the group is enrolling patients onto the protocol at Long Island Jewish Medical Center itself.

HspE7 is used as a therapeutic vaccine. The drug is a fusion protein linking together a heat shock protein, which should stimulate the immune system, and the HPV-16 E7 protein. (Although the E7 proteins from HPV-16, -11, and -6 are not identical, scientists hypothesize that they are similar enough to induce an anti-HPV immune response in RRP-affected individuals.) In an open-label multicenter trial, Dr. Derkay and colleagues treated 27 pediatric RRP patients with HspE7. Following an initial surgery to remove the papillomas, each patient received three subcutaneous injections of the fusion protein over three months. The primary endpoint of the trial was to determine whether treatment increased the interval between surgeries after the three-month treatment period as compared with the four surgeries prior to HspE7 treatment. The mean increase in duration between surgeries for all patients was 93% following therapy, suggesting that the agent was active in RRP.

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Departments, Head and Neck, Medical Education, Pediatric, Practice Focus Tagged With: cancer, diagnosis, HPV, pediatrics, prevention, radiation, research, respiratory papillomatosis, surgery, treatment, tumor, vaccineIssue: October 2006

You Might Also Like:

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Some Studies Predict a Shortage of Otolaryngologists. Do the Numbers Support Them?
    • Vertigo in the Elderly: What Does It Mean?
    • Complications for When Physicians Change a Maiden Name
    • Neurogenic Cough Is Often a Diagnosis of Exclusion
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • Tympanoplasty Tips: Otology Experts Give Advice on the Procedure
    • How Treatment for Obstructive Sleep Apnea (OSA) Is Evolving to Give Patients a Better Night’s Sleep
    • Vestibular Schwannoma Position Relative to Internal Auditory Canal Helps Predict Postoperative Facial Function
    • Vocal Fold Lipoaugmentation Provides Long-Term Voice Improvements for Glottal Insufficiency
    • Upper Lateral Cartilage Mucosal Flap Enables the Successful Closure of Larger Septal Perforations

Polls

Do you think there will be a shortage of otolaryngologists in the next five to 10 years?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2022 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.